Modulation of NF-κB, p53 and Bcl-2 in apoptosis induced by cisplatin in HeLa cells

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 381, Issue 1, 1997, Pages 67-75

  Maldonado, Vilma ^a   Meléndez Zajgla, Jorge ^a   Ortega, Arturo ^b  

^a Cellular Biology Section   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Apoptosis; Bcl 2; Cisplatin; HeLA cell; NF B; p53

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; HELA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MODULATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CISPLATIN; ELECTROPHORESIS; HELA CELLS; HUMANS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-REL; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTOR RELB; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0343811694     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00150-4     Document Type: Article

References (53)

1. Wyllie A.H. Apoptosis (The 1992 Frank Rose Memorial Lecture). Br. J. Cancer. 67:1992;205-208.
2. Kerr J.F.R., Winterford C.M., Harmon B.V. Apoptosis. Cancer. 73:1994;2013-2026.
3. Prives C., Manfredi J.J. The p53 tumor suppressor protein: meeting review. Genes Dev. 7:1993;529-534.
4. Huibregtse J.M., Scheffner M., Howley P.M. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Cell. Biol. 13:1993;775-784.
5. Benveniste P., Cohen A. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc. Natl. Acad. Sci. USA. 92:1995;8373-8377.
6. Wang Y., Szekely L., Okan I., Klein G., Wiman K.G. Wild-type p53 triggered apoptosis is inhibited by Bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene. 8:1993;3427-3431.
7. Symond H., Krall L., Remington L., Saez-Rebles M., Lowe S., Jacks T., Van Dyke T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78:1994;703-771.
8. Nuñez G., Clarke M.F. The Bcl-2 family of proteins: regulators of cell death and survival. Trends Cell. Biol. 4:1994;399-403.
9. Chiou S., Rao L., White E. Bcl-2 blocks p53-dependent Apoptosis. Mol. Cell. Biol. 14:1994;2556-2563.
10. Oliver F.J., Marvel J., Collins M.K.L., López-Rivas A. Bcl-2 oncogene protects a bone marrow-derived pre-B cell line from 5′-fluor, 2′-deoxyuridine-induced apoptosis. Biochem. Biophys. Res. Commun. 1:1993;126-132.
11. Kane D.J., Sarafian T.A., Anton R., Hahh H., Butler E., Selverstone J., Ord T., Bredesen D.E. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science. 262:1993;1274-1277.
12. Hockenbery D.M., Oltvai Z.N., Yin X.M., Milliman C.L., Korsmeyer S.J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 74:1993;241-251.
13. Barry M.A., Behnke C.A., Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40:1990;2353-2362.
14. Maldonado V., Melendez J., Gonzalez H., Ortega A. Internucleosomal DNA cleavage in HeLa Cells exposed to cisplatin. Biochem. Mol. Biol. Int. 37:1994;691-696.
15. Ormerod M.G., O'Neill C.F., Robertson D., Harrap K.R. Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp. Cell. Res. 211:1994;231-237.
16. Fichtinger-Schepman A.M.J., van der Veer J.L., den Hartog J.H.J., Lohman P., Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum (II) with DNA: formation, identification, and quantitation. Biochemistry. 24:1985;707-713.
17. Sorenson C.S., Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity:role of G2 arrest and DNA double-strand breaks. Cancer Res. 48:1988;4484-4488.
18. Sorenson C.M., Barry M.A., Eastman A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J. Natl. Cancer Inst. 82:1990;749-755.
19. Masuda H., Tanaka T., Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem. Biophys. Res. Commun. 203:1994;1175-1180.
20. Zhang J.G., Lindup E.W. Cisplatin-nephrotoxicity: decreases in mitochondria protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. Biochem. Pharmacol. 47:1995;1127-1135.
21. Haecker G., Vaux D.L. Viral, worm and radical implications for apoptosis. Trends Biochem. Sc. 19:1994;99-100.
22. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 12:1993;2005-2015.
23. Wu H., Lozano G. NF-κB activation of p53. J. Biol. Chem. 31:1994;20067-20074.
24. Haldar S., Negrini M., Monne M., Sabbioni S., Croce C.M. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54:1994;2095-2097.
25. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
26. Pande S.V., Murthy M.S.R. A modified micro-Bradford procedure for elimination of interference from sodium dodecyl sulfate, other detergents and lipids. Anal. Biochem. 220:1994;424-426.
27. Frantz B., Nordby E.C., Bren G., Steffan N., Paya C.V., Kincaid R.L., Tocci M.J., O'Keefe S.J., O'Neill E.A. Calcineurin acts in synergy with PMA to inactivate IκB/MAD3, an inhibitor of NK-κB. EMBO J. 13:1994;861-870.
28. Zabel U., Schreck R., Baeuerle P.A. DNA Binding of purified transcription factor NF-κB. J. Biol. Chem. 266:1991;252-260.
29. Kuerbirtz S.J., Plunkett B.S., Wals W.V., Kastan M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:1992;7491-7495.
30. Zabel U., Henkel T., dos Santos Silva M., Baeuerle P.A. Nuclear uptake control of NF-κB by MAD-3, an IκB protein present in the nucleus. EMBO J. 10:1993;4159-4167.
31. Cressman D.E., Taub R. IκBα can localize in the nucleus but shows no direct transactivation potential. Oncogene. 8:1993;2567-2573.
32. Arenzana-Seisdedos F., Thompson J., Rodriguez M.S., Bacheleire F., Thomas D., Hay R.T. Inducible Nuclear expression of newly synthesized IκBα negatively regulates DNA-Binding and transcriptional activities of NF-κB. Mol. Cell. Biol. 15:1995;2689-2696.
33. Arenzana-Seisdedos F., Turpin P., Rodriquez M., Thomas D., Hay R.T., Virelizier J.L., Daremont C. Nuclear localization of IκBα promotes active transport of NF-κB from the nucleus to the cytoplasm. J. Cell Sci. 110:1997;369-378.
34. Pereira D.S., Kushner D.B., Ricciardi R.P., Graham F.L. Testing NF-κB1-p50 antibody specificity using knockout mice. Oncogene. 13:1996;445-446.
35. Siebenlist U., Franzoso G., Brown K. Structure, regulation and function of NF-κB. Annu. Rev. Cell. Biol. 10:1994;4055-4455.
36. Schreck R., Aldermann K., Baeuerle P.A. NF-κB: an oxidative stress-responsive transcription factor of eukaryotic cells. Free Radical Res. Commun. 17:1992;221-237.
37. Schreck R., Meier B., Maennel D.N., Droge W., Baeuerle P.A. Dithiocarbamates as potent inhibitor of nuclear factor kB activation of the NF-κB transcription factor and HIV-1. EMBO J. 10:1992;2247-2258.
38. Neiman P.E., Thomas S.J., Loring G. Induction of apoptosis during normal and neoplastic B-cell development in the bursa of Fabricius. Proc. Natl. Acad. Sci. USA. 88:1991;5857-5861.
39. Abbadie C., Kabrun N., Bouali F., Smardova J., Stehelin D., Vandenbunder B., Enrietto P.J. High levels of c-rel expression are associated with programmed cell death in the developing avian embryo and in bone marrow cells in vitro. Cell. 75:1993;899-912.
40. Beg A.A., Baltimore D. An essential role for NF-κB in preventing TNF-α-induced cell death. Science. 274:1996;782-784.
41. Wang C.Y., Mayo M.W., Baldwin A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 274:1996;784-787.
42. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-α-induced apoptosis by NF-κB. Science. 274:1900;787-789.
43. Ryan J.J., Prochownik E., Gottlieb C.A., Apel I.J., Merino R., Nuñez G., Clarke M.F. c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc. Natl. Acad. Sci. USA. 91:1994;5878-5882.
44. Strasser A., Harris A.W., Jacks T., Cory S. DNA Damage can induce Apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 79:1994;329-339.
45. Gujuluva C.N., Baek J.H., Shin K.H., Cherrick H.M., Park N.H. Effect of UV-irradiation on cell cycle, viability and the expression of p53, gadd153 and gadd45 genes in normal and HPV-immortalized human oral keratinocytes. Oncogene. 9:1994;1819-1827.
46. Schwarz E., Freese U.K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., Zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 314:1985;111-114.
47. Mansur C.P., Androphy E.J. Cellular transformation by papillomavirus oncoproteins. Biochim. Biophys. Acta. 1155:1993;323-345.
48. Spitkovsky D., Aengeneyndt F., Braspenning J., von Knebel Doeberitz M. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene. Oncogene. 13:1996;1027-1035.
49. Zhang N., Song Q., Lu H., Lavin M.F. Induction of p53 and increased sensitivity to cisplatin in ataxiatelangiectasia cells. Oncogene. 13:1996;655-659.
50. Kondo S., Barna B.P., Kondo Y., Tanaka Y., Casey G., Liu J., Morimura T., Kaakai R., Peterson J.W., Werbel B., Barnett G.H. WAF1/CIPI increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene. 13:1996;1279-1285.
51. Thomas M., Massimi P., Banks L. HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact recognition sequence. Oncogene. 13:1996;471-480.
52. Guillouf C., Rosselli F., Krishnaraju K., Moustacchi E., Horrman B., Liebermann D.A. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene. 10:1995;2263-2270.
53. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., Reed J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.